PLIVA develops and manufactures finished dosage forms and active pharmaceutical ingredients on its sites in Zagreb and Savski Marof. PLIVA in Croatia currently has almost 1,700 employees, and it invests considerable and continuous efforts in their professional development. The strength of our company lies in the wealth of diversity, expertise of our employees and their commitment to the achievement of business goals. For generations the credit for PLIVA’s success goes to them.
PLIVA has state-of-the-art development and production capacities and markets a broad range of high-quality generics offering superior therapeutic solutions in a number of markets in Europe and worldwide. PLIVA's product portfolio includes oral and injectable dosage forms, creams/ointments, over-the-counter products and active pharmaceutical ingredients. Prescription medicines are sold to wholesalers and hospitals, while over-the-counter products may be found in pharmacies.
PLIVA bases its operations on competitive production, continuous customer care and cooperation with all healthcare system segments in both Croatia and throughout the region. The integration with Teva has additionally strengthened PLIVA's leading position in Croatia and in key international markets where PLIVA can offer a broad portfolio of high quality generic medicines.
PLIVA's product portfolio covers the following major therapeutic groups: cardiovascular, gastrointestinal, anti-infectives, oncology, musculoskeletal, neurological and psychiatric diseases.
Thanks to its strong brand, PLIVA holds the leading position in Croatia and its brand is highly recognized and appreciated across the region. Its value has been additionally confirmed by the Superbrands Croatia 2008 award, which is presented only to superior Croatian brands.
PLIVA entered a new investment cycle in 2011. It plans to invest USD 120 million over the next three to five years in the new production plant in Savski Marof and the expansion of production capacities in Zagreb. The new production plant in Savski Marof will create about 100 new jobs, which will directly contribute to the strengthening of the Croatian economy.
PLIVA in Croatia is both one of the largest companies and one of the leading exporters: in 2009 it ranked third with exports amounting to HRK 2 billion. PLIVA's major markets are Croatia, the USA and Russia. Its other important markets are Poland, Ukraine, Bosnia and Herzegovina, the Czech Republic, the United Kingdom, Kazakhstan and Hungary.
PLIVA's production chain comprises of over 1000 suppliers with turnover exceeding HRK 1 billion. With its broad product portfolio, PLIVA is also a reliable partner to the Croatian healthcare system, and an active member of the Croatian Employers' Association (Drug Manufacturers Association), Croatian Chamber of Commerce and other business associations.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 15 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
With more than a century of experience in the healthcare industry, the Company enjoys a firmly established international presence, operating through a carefully tailored network of worldwide subsidiaries. Headquartered in Israel, above 80% of Teva's sales, which totalled US$16.1 billion in 2010, are in North America and Europe. Teva has over 40,000 employees worldwide and production facilities in Israel, North America, Europe and Latin America.
1 to 31 in 10 Seconds
1 of the largest generic pharmaceutical companies
Top 15 global pharmaceutical companies
53 Billion tablets manufactured in 2009
Operations in 60 countries
Distribution of products to over 100 markets
Global product portfolio of more than 1,250 molecules
2,500 prescriptions every minute
Close to 40,000 employees in Teva
$13.9 billion in sales and $3 billion in non GAAP net income in 2009
Strategic goal of $31 billion in sales by 2015
Code of Business
Honesty and fair process are important in Teva, both from the standpoint of work relations between employees within the company and in its relations with external customers, suppliers & shareholders
The ethical behaviour & integrity of Teva's people worldwide have always been an integral part of Teva's culture
As a public company traded in the US, Teva is subject to the Sarbanes Oxley Act, which requires the adoption of a Code of Business Conduct and is required to be compliant with the requirements of the Foreign Corrupt Practices Act (FCPA).
In accordance with this, Teva adopted the Code of Business Conduct at the beginning of 2004 and has developed an FCPA policy
Corporate Social Responsibility
Teva is committed to improving global healthcare, and recognize our responsibility to invest in and support the communities we serve
We focus our involvement in the community on promoting (local) healthcare and educational initiatives as well as additional activities which contribute to the well being of the communities we live in.
We are proud of our many employees who volunteer, contribute and lend their support to the communities in which they live and work